C. F. Deacon

发表

Targeting the intestinal L-cell for obesity and type 2

Jens J. Holst, N. J. Wewer, Ehrenreich Kuhre, 2014 .

Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas

H. Lebovitz, C. Deacon, C. F. Deacon, 2016, Diabetes, obesity & metabolism.

GLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice

N. Calcutt, M. Fineman, C. Jolivalt, 2011, Diabetes, obesity & metabolism.

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.

T. Hughes, C. Deacon, P. Bie, 2002, The Journal of endocrinology.

The Effect of Exogenous Glp-1 on Food Intake Is Lost in Male Truncally Vagotomized Subjects with Pyloroplasty Study Protocol

J. Holst, C. Hovendal, B. Hartmann, 2022 .

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

C. Orskov, C. F. Deacon, J. J. Holst, 1999, Endocrinology.

Ghrelin secretion in humans – a role for the vagus nerve?

J. Holst, B. Hartmann, T. Vilsbøll, 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review

C. Deacon, C. F. Deacon, C. F. Deacon, 2011, Diabetes, obesity & metabolism.

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

J. Holst, T. Hughes, C. Deacon, 1998, Diabetes.

Effects of saxagliptin on β‐cell stimulation and insulin secretion in patients with type 2 diabetes

J. Holst, S. Mudaliar, R. Henry, 2011, Diabetes, obesity & metabolism.

The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study

C. Rayner, J. E. Stevens, M. Nauck, 2012, Alimentary pharmacology & therapeutics.

No evidence of tachyphylaxis for insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) in subjects with type 2 diabetes, their first-degree relatives, or in healthy subjects

J. Holst, M. Kahle, M. Nauck, 2020, Peptides.

Dissociated incretin hormone response to protein versus fat ingestion in obese subjects

C. F. Deacon, J. J. Holst, Richard D. Carr, 2011, Diabetes, obesity & metabolism.

Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects

J. Holst, M. Nauck, C. Deacon, 2007, Diabetologia.

The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects.

J. Holst, T. Vilsbøll, F. Knop, 2014, European journal of endocrinology.

Long‐term exendin‐4 treatment delays natural deterioration of glycaemic control in diabetic Goto–Kakizaki rats

B. Hartmann, C. Deacon, C. Ørskov, 2009, Diabetes, obesity & metabolism.